Literature DB >> 2054777

In vivo 14N nuclear magnetic resonance spectroscopy of tumors: detection of ammonium and trimethylamine metabolites in the murine radiation induced fibrosarcoma 1.

M P Gamcsik1, I Constantinidis, J D Glickson.   

Abstract

The in vivo 14N nuclear magnetic resonance spectra of s.c. implanted murine radiation induced fibrosarcomas (RIF-1) display narrow resonances assignable to betaine and other trimethylamines and broad resonances due to amino acids and peptides. In 19 of the 41 tumors studied a distinct resonance from the ammonium ion is detectable. The accumulation of ammonium in the tumor to nuclear magnetic resonance detectable levels may result from glutaminolysis (a possible pathway for energy production in the tumor), from the degradation of peptides and proteins, or from the deamination of adenine nucleotides. Estimates of the tissue ammonium concentration were obtained from the in vivo tumor spectrum and the spectrum of the nonlabile trimethylamines in the perchloric acid extract. In the extract, the 14N resonances of betaine, carnitine, choline, phosphorylcholine, and glycerophosphorylcholine were resolved, and a relatively high level of tissue urea was observed. Spin-lattice relaxation times were obtained for the 14N nucleus of each of these metabolites in phosphate buffer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2054777

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  (1)H- (31)P soft-HSQC pulse sequence specifically for detecting phosphomono- and diesters in biological samples.

Authors:  Xi-an Mao; Bin Jiang; Ling Jiang; Maili Liu
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

2.  Physiological Role of Glutamate Dehydrogenase in Cancer Cells.

Authors:  Rafael Moreno-Sánchez; Álvaro Marín-Hernández; Juan C Gallardo-Pérez; Silvia C Pacheco-Velázquez; Diana X Robledo-Cadena; Joaquín Alberto Padilla-Flores; Emma Saavedra; Sara Rodríguez-Enríquez
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.